Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RCKT Stock Forecast 2026-2027
$3.72
Current Price
$406.20M
Market Cap
Buy 5
Hold 6
Sell 2
Wall St Analyst Ratings
Distance to RCKT Price Targets
+330.1%
To High Target of $16.00
+168.8%
To Median Target of $10.00
-19.4%
To Low Target of $3.00
RCKT Price Momentum
-8.6%
1 Week Change
+35.3%
1 Month Change
+22.0%
1 Year Change
+6.0%
Year-to-Date Change
-31.7%
From 52W High of $5.45
+47.0%
From 52W Low of $2.53
📊 TOP ANALYST CALLS
Did RCKT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rocket Pharmaceuticals is one of their latest high-conviction picks.
Latest RCKT Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, RCKT has a neutral consensus with a median price target of $10.00 (ranging from $3.00 to $16.00). The overall analyst rating is Buy (7.1/10). Currently trading at $3.72, the median forecast implies a 168.8% upside. This outlook is supported by 5 Buy, 6 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RCKT Analyst Ratings
5
Buy
6
Hold
2
Sell
RCKT Price Target Range
Low
$3.00
Average
$10.00
High
$16.00
Current: $3.72
Latest RCKT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RCKT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 11, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $11.00 |
| Mar 30, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| Mar 27, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 2, 2026 | Goldman Sachs | Sell | Maintains | $N/A | |
| Feb 27, 2026 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Nov 18, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Nov 18, 2025 | JP Morgan | Underweight | Downgrade | $N/A | |
| Oct 14, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Oct 3, 2025 | Leerink Partners | Market Perform | Maintains | $N/A | |
| Aug 20, 2025 | B of A Securities | Buy | Upgrade | $N/A | |
| Aug 20, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 11, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 8, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Jul 25, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jul 25, 2025 | B of A Securities | Neutral | Downgrade | $N/A | |
| Jul 24, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jul 24, 2025 | Needham | Hold | Maintains | $N/A | |
| Jun 17, 2025 | UBS | Buy | Maintains | $N/A | |
| Jun 3, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 28, 2025 | B of A Securities | Buy | Maintains | $N/A |
Rocket Pharmaceuticals Inc. (RCKT) Competitors
The following stocks are similar to Rocket Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rocket Pharmaceuticals Inc. (RCKT) Financial Data
Rocket Pharmaceuticals Inc. has a market capitalization of $406.20M with a P/E ratio of -1.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -64.4%.
Valuation Metrics
Market Cap
$406.20M
Enterprise Value
$307.33M
P/E Ratio
-1.8x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+35.5%
Current Ratio
6.1x
Debt/Equity
10.4x
ROE
-64.4%
ROA
-35.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rocket Pharmaceuticals Inc. (RCKT) Business Model
About Rocket Pharmaceuticals Inc.
What They Do
Develops gene therapies for rare pediatric diseases.
Business Model
Rocket Pharmaceuticals focuses on developing innovative gene therapies using advanced AAV and LV technologies. The company generates revenue primarily through partnerships and collaborations with academic institutions and healthcare organizations, which support its clinical programs and the development of its therapies for rare genetic disorders.
Additional Information
Founded in 2015 and headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals aims to transform treatment paradigms for pediatric conditions with significant unmet medical needs. Its pipeline targets several serious diseases, and the company has established collaborations with prestigious institutions such as the Children's Hospital of Philadelphia and the Fred Hutchinson Cancer Research Center.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
202
CEO
Dr. Gaurav D. Shah M.D.
Country
United States
IPO Year
2015
Website
www.rocketpharma.comRocket Pharmaceuticals Inc. (RCKT) Latest News & Analysis
Latest News
Quick Summary
Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. The voucher was granted by the FDA in March 2026 related to KRESLADI approval.
Why It Matters
Rocket Pharmaceuticals' $180 million sale of a Priority Review Voucher enhances its cash position, signaling strong market confidence and potential for growth in genetic therapies, attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Rocket Pharmaceuticals, Inc. (RCKT) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, discussing its developments and strategies in the healthcare sector.
Why It Matters
Rocket Pharmaceuticals' presentation at a major healthcare conference signals potential developments in their pipeline, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Rocket Pharmaceuticals, Inc. (RCKT) presented at the Jefferies Global Healthcare Conference 2026, highlighting key developments and strategic insights for investors.
Why It Matters
Rocket Pharmaceuticals' presentation at a major healthcare conference signals potential updates on its pipeline, which can influence stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Rocket Pharmaceuticals, Inc. will present at the Jefferies Global Healthcare Conference and Goldman Sachs Healthcare Conference, featuring CEO Gaurav Shah.
Why It Matters
Rocket Pharmaceuticals' participation in major healthcare conferences highlights its commitment to growth and innovation, potentially attracting investor interest and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Rocket Pharmaceuticals shares declined following a larger-than-expected Q1 loss while the company prepares for the launch of its newly approved gene therapy, Kresladi.
Why It Matters
Rocket Pharmaceuticals' wider Q1 loss may indicate financial strain, impacting investor confidence as the company shifts focus to Kresladi's market launch, which carries both potential and risk.
Source: Zacks Investment Research
Market Sentiment:
Negative
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
2 months ago
Quick Summary
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q1 2026 financial results, focusing on advancing its cardiovascular gene therapy portfolio and reinitiating dosing in a three-patient cohort.
Why It Matters
Rocket Pharmaceuticals' progress in gene therapies and reinitiating patient dosing signals potential advancements in treatment options, impacting future revenue and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About RCKT Stock
What is Rocket Pharmaceuticals Inc.'s (RCKT) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Rocket Pharmaceuticals Inc. (RCKT) has a median price target of $10.00. The highest price target is $16.00 and the lowest is $3.00.
Is RCKT stock a good investment in 2027?
According to current analyst ratings, RCKT has 5 Buy ratings, 6 Hold ratings, and 2 Sell ratings. The stock is currently trading at $3.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RCKT stock?
Wall Street analysts predict RCKT stock could reach $10.00 in the next 12 months. This represents a 168.8% increase from the current price of $3.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rocket Pharmaceuticals Inc.'s business model?
Rocket Pharmaceuticals focuses on developing innovative gene therapies using advanced AAV and LV technologies. The company generates revenue primarily through partnerships and collaborations with academic institutions and healthcare organizations, which support its clinical programs and the development of its therapies for rare genetic disorders.
What is the highest forecasted price for RCKT Rocket Pharmaceuticals Inc.?
The highest price target for RCKT is $16.00 from at , which represents a 330.1% increase from the current price of $3.72.
What is the lowest forecasted price for RCKT Rocket Pharmaceuticals Inc.?
The lowest price target for RCKT is $3.00 from at , which represents a -19.4% decrease from the current price of $3.72.
What is the overall RCKT consensus from analysts for Rocket Pharmaceuticals Inc.?
The overall analyst consensus for RCKT is neutral. Out of 2 Wall Street analysts, 5 rate it as Buy, 6 as Hold, and 2 as Sell, with a median price target of $10.00.
How accurate are RCKT stock price projections?
Stock price projections, including those for Rocket Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 2:50 PM UTC